Double-blind, placebo-controlled trial of oral tacrolimus (FK506) in the management of hospitalized patients with steroid-refractory ulcerative colitis

2012 ◽  
Vol 18 (5) ◽  
pp. 803-808 ◽  
Author(s):  
Haruhiko Ogata ◽  
Jun Kato ◽  
Fumihito Hirai ◽  
Nobuyuki Hida ◽  
Toshiyuki Matsui ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Controlled Trial ◽  
Hospitalized Patients ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Steroid Refractory

Interferon-β-1a for the Treatment of Steroid-Refractory Ulcerative Colitis: A Randomized, Double-Blind, Placebo-Controlled Trial

2005 ◽  
Vol 3 (6) ◽  
pp. 581-586 ◽  
Author(s):  
E MUSCH ◽  
T ANDUS ◽  
W KRUIS ◽  
A RAEDLER ◽  
M SPEHLMANN ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Controlled Trial ◽  
Interferon Β ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Steroid Refractory

389 A Randomized, Double-Blind, Placebo-Controlled Trial of Basiliximab with Concomitant Corticosteroids in Steroid-Refractory Ulcerative Colitis

2009 ◽  
Vol 136 (5) ◽  
pp. A-65 ◽  
Author(s):  
Bruce E. Sands ◽  
William J. Sandborn ◽  
Tom J. Creed ◽  
Colin M. Dayan ◽  
Gert A. Van Assche ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Controlled Trial ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Steroid Refractory

Lyophilised oral faecal microbiota transplantation for ulcerative colitis (LOTUS): a randomised, double-blind, placebo-controlled trial

2021 ◽  
Author(s):  
Craig Haifer ◽  
Sudarshan Paramsothy ◽  
Nadeem O Kaakoush ◽  
Aiasha Saikal ◽  
Simon Ghaly ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Controlled Trial ◽  
Faecal Microbiota ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Faecal Microbiota Transplantation

Additive factor XIII treatment for severe ulcerative colitis. A double blind placebo-controlled trial

1998 ◽  
Vol 114 ◽  
pp. A1014 ◽  
Author(s):  
W. Kruis ◽  
H. Malchow ◽  
M. Behnke ◽  
J. Emmrich ◽  
J. Hämling ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Factor Xiii ◽  
Controlled Trial ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Severe Ulcerative Colitis

Curcumin Maintenance Therapy for Ulcerative Colitis: Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial

2006 ◽  
Vol 4 (12) ◽  
pp. 1502-1506 ◽  
Author(s):  
Hiroyuki Hanai ◽  
Takayuki Iida ◽  
Ken Takeuchi ◽  
Fumitoshi Watanabe ◽  
Yasuhiko Maruyama ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Maintenance Therapy ◽  
Controlled Trial ◽  
Double Blind ◽  
Double Blind Placebo

Wheat Grass Juice in the Treatment of Active Distal Ulcerative Colitis: A Randomized Double-blind Placebo-controlled Trial

2002 ◽  
Vol 37 (4) ◽  
pp. 444-449 ◽  
Author(s):  
E. Ben-Arye ◽  
E. Goldin ◽  
D. Wengrower ◽  
A. Stamper ◽  
R. Kohn ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Controlled Trial ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Distal Ulcerative Colitis

scholarly journals Chinese herbal extract granules combined with 5-aminosalicylic acid for patients with moderately active ulcerative colitis: study protocol for a multicenter randomized double-blind placebo-controlled trial

2020 ◽  
Author(s):  
Zhaofeng Shen ◽  
Kai Zheng ◽  
Jiandong Zou ◽  
Peiqing Gu ◽  
Jing Xing ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Remission Rate ◽  
Controlled Trial ◽  
Herbal Extract ◽  
Aminosalicylic Acid ◽  
Clinical Trial Registry ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Chinese Herbal ◽  
Superiority Trial

Abstract Background Ulcerative colitis (UC) is an intestinal inflammatory disease characterized by inflammation of the colonic mucosa. With unknown pathogenesis, it has become a chronic lifetime disorder worldwide. In patients with moderately active UC, several therapies (e.g. aminosalicylates, corticosteroids, immunosuppressants and biologics) are recommended for induction (or maintenance) of remission. Given the side effects and disease burden, it is difficult for most patients to achieve ideal treatment goals in clinical practice. Chinese herbal medicine (CHM), as a complementary therapy, has been widely used in the management of UC in China. Qing-Chang-Hua-Shi granule (QCHS) is a classical Chinese herbal formula. Our preliminary study suggested that the QCHS decoction has a significant effect on patients with moderately active UC. However, its effectiveness and safety has not been evaluated convincingly. Therefore, we designed this protocol to investigate the efficacy of QCHS granule for moderately active UC. Methods This is a multicenter, randomized, double-blind, placebo-controlled, superiority trial. A total of 120 patients with moderately active UC will be recruited from 10 hospitals in China. Each eligible participant will be randomly assigned to receive QCHS granule or placebo twice daily for 12 weeks. Both groups will be given basic treatment with mesalazine (4 g/d). The primary outcomes are the clinical response (remission) rate. The secondary outcomes are health-related quality of life, endoscopic response rate, mucosal healing rate and inflammatory markers (e.g. Fecal calprotectin and CRP). The whole study period will last 36 weeks, including 24 weeks follow-up time. According to the intention-to-treat principle, variables will be assessed at 2, 4, 6, 8, 10 and 12 weeks after study commencement. Discussion This is the first prospective, multicenter, randomized, double-blind, placebo-controlled, superiority trial regarding Chinese herbal extract granules in the management of moderately active UC. We aim to investigate the superiority of QCHS granules over placebo in terms of induction of remission. The findings will provide convincing evidence on the efficacy and safety of QCHS granules for moderately active UC, which may help clinical practitioners, UC patients and policymakers make more informed choices in the decision-making. Trial registration: Chinese Clinical Trial Registry, ChiCTR-IOR-14005554. Registered on 27 November 2014.

Sign in / Sign up

Export Citation Format

Share Document